Epitech Group S.P.A.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Sep 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 21, 2027The maintenance fee for Composition of N-palmitoyl-ethanolamide and Rutin in co-micronized form (US 11,819,511) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,470,373 | Composition containing ultra-micronized palmitoyl-ethanolamide In force · From the USPTO record | In force | From the USPTO record | |
| US 8,663,701 | Compositions containing ultra-micronized palmitoyl-ethanolamide In force · From the USPTO record | In force | From the USPTO record | |
| US 9,402,818 | Use of amides of mono- and dicarboxylic acids in the treatment of renal diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 8,546,352 | Pharmacological preparation for topical use containing N-palmitoyl-vanillamide In force · From the USPTO record | In force | From the USPTO record | |
| US 9,512,091 | Compositions and methods for the modulation of specific amidases for N-acylethanolamines for use in the therapy of inflammatory diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,522,192 | Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides In force · From the USPTO record | In force | From the USPTO record | |
| US 9,399,031 | Combined use of amides of mono- and dicarboxylic acids and silymarin in the treatment of renal diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 12,364,678 | Pharmaceutical composition comprising palmitoylethanolamide and L- Acetylcarnitine In force · From the USPTO record | In force | From the USPTO record | |
| US 9,668,986 | Ophthalmic, intra-articular or intravesical preparations containing N-acyl-ethanolamines In force · From the USPTO record | In force | From the USPTO record | |
| US 9,801,836 | Using palmitoylethanolamide in combination with opioids In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 16: 2 patents in force now held by others · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned · 10 no status recorded